New ways for precise assessment on ADHD and other disorders with cognitive impairments

OPATUS CPTa: New ways in precise diagnostics and therapy support for optimized treatment results in ADHD and other neuropsychiatric disorders

View my new book on OPATUS CPTa (English Edition) https://www.amazon.de/dp/B0BB5MCC7J

The German edition has been published as #OPATUS #CPTa Neue Wege in pr?ziser Diagnostik und Therapiebegleitung für optimierte Behandlungsergebnisse bei ADHS und anderen neuropsychiatrischen Erkrankungen https://www.amazon.de/dp/B0B9QYPDWT

The Opatus Test measures impulsivity, attention and restlessness. The CPTA alone is not an ADHD test. It objectively measures impulsivity, activity and inattentiveness (which happen to be the core core symptoms of ADHD).

The clinician then has to decide, why/how these entities/parameters can help him/her to best help the patient in the form of diagnosis or to monitor treatments.

This also opens up areas of application in other indications such as mental fatigue, Parkinson's, schizophrenia, or assessments of attention, for example after concussions or other brain-organic disorders.

The CPTA should also be affordable for clinics with a limited number of patients. Pay-per-use and no fixed costs and no contracts were an option. The aim was also, to enable remote management, so that patients who live in the countryside, where a clinic visit is an all-day project, would be able to to take the same test as patients from the big city.

The CPTa runs on iPhones and iPod touch. The test uses the built-in sensors (accelerometer and gyroscope) for the activity measurements.

We postulate that the measured data are more representative from a more "natural" test (typing on a smartphone) because this is what today's generation is familiar with from everyday life.

In addition, the OPATUS CPTa allows testing in real situations, for example during a lesson at school. For mobile examinations, the CPTa can easily be done at workplaces, at schools or by the patient at home.

This means that the examination is carried out in a realistic environment and false positive or negative results can be reduced.

In clinical practice, it has now become an indispensable standard test within my battery of tests, which is carried out on all patients who visit our practice.

In the meantime, approximately 10,000 tests have been carried out at our practice and we have a cooperation with OPATUS.se to optimize the test and the presentation of the test results and also contributed to the creation of a norm database for children and adults.

Since 2018, the test has CE certification in the EU.

The concept, to integrate this test into the regular assessment has been shown in my #bestselling book #ADHDisCurable:

This shows an example of test results:

Increasing Impulsivity as early as 2 min. Volatility and slowing down, z-score clearly conspicuous for omission errors and total score.

The examples show that the OPATUS CPTa is a high-precision examination instrument with which the smallest changes in the state of health or the ability to cope with concentration tasks and, as a secondary finding, also the degree of motor restlessness can be measured.

In this respect, it lends itself to being used as a standard for clinical studies that deal with the topic of ADHD as well as with other neuropsychiatric or psychiatric disorders (e.g., indirect parameters in depression, PTSD under treatment (psychotherapy or medication etc. can be measured.

The OPATUS CPTa also offers the possibility, for example in the case of ADHD treatments, to identify learning effects that make a dose adjustment necessary, or to support an individualized dose determination in advance, which in turn, helps to avoid under- or overdosing.

The goal of differentiated treatment is to support adifferentiated brain maturation.

This represents one of the greatest challenges in psychiatry in the coming decades: an ever better understanding of the brain-organic correlates of psychiatric disorders, a better understanding of what psychotropic drugs actually do and at which receptors, and accordingly help to develop a treatment that is better and better adapted to the patient.

More information on www.meyers-hamburg.com (view English pages).